Zafrin 2.5 Tablet
Olanzapine
2.5mg
Magnus Pharma Pvt. Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 3.00 NPR |
Available as:
Indications
Zafrin 2.5 Tablet is used for:
Schizophrenia, Bipolar disorder, Agitation, Mania
Adult Dose
Oral
Schizophrenia
Adult: 5-10 mg/day initially; if necessary, may be titrated upward in increments of 5 mg/day at intervals >1 week
Maintenance: 10-20 mg/day; not to exceed 20 mg/day
Bipolar Mania
Used as monotherapy or in combination with lithium or valproate
Monotherapy: 10-15 mg/day PO initially
Adjunct to lithium or valproate: 10 mg/day PO initially
Maintenance: 5-20 mg/day PO; not to exceed 20 mg/day
Depression in bipolar disorder
Use in combination with fluoxetine
5 mg in evening; adjusted to range of 5-12.5 mg/day; may be increased up to 20 mg/day in resistant depression
Hepatic impairment: Initial: 5 mg daily.
Child Dose
Oral
Bipolar I Disorder (Manic or Mixed Episodes)
<13 years: Safety and efficacy not established
13-17 years: 2.5-5 mg/day PO initially; target dosage, 10 mg/day; adjust by increments/decrements of 2.5-5 mg; dosage range, 2.5-20 mg/day
Schizophrenia
<13 years: Safety and efficacy not established
13-17 years: 2.5-5 mg/day PO initially; target dosage, 10 mg/day; adjust by increments/decrements of 2.5-5 mg; dosage range, 2.5-20 mg/day
Renal Dose
Renal impairment: Initial: 5 mg daily.
Administration
May be taken with or without food.
Contra Indications
Angle-closure glaucoma; lactation. IM: History of CVS disease, heart surgery.
Precautions
Patient w/ cerebrovascular disease or conditions predisposing to hypotension, benign prostatic hyperplasia, paralytic ileus, DM, Parkinson's disease, history of blood dyscrasias, bone marrow depression, hypereosinophilic disorders, myeloproliferative disease, history of seizures or conditions that lower the seizure threshold. IM: Acute MI, unstable angina, severe hypotension or bradycardia, sick sinus syndrome, recent heart surgery. Elderly w/ dementia-related psychosis. Hepatic and renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause somnolence and dizziness, if affected, avoid driving and operating machinery. Avoid cigarette smoking. Monitoring Parameters Monitor BP, pulse and resp rate for at least 4 hr after IM inj. Clinical monitoring for hyperglycaemia, plasma lipids and wt.
Lactation: Drug enters breast milk; not recommended
Pregnancy-Lactation
Interactions
Olanzapine may antagonise the effects of levodopa and dopamine agonists. Drugs that induce CYP1A2 or glucuronyl transferase enzymes e.g. omeprazole and rifampicin, may increase olanzapine clearance. Inhibitors of CYP1A2 may potentially inhibit olanzapine elimination. Carbamazepine may increase the clearance of olanzapine. Concomitant admin of activated charcoal reduced the oral bioavailability of olanzapine by 50-60%. Caution should be taken when olanzapine is administered with centrally acting drugs and alcohol.
Adverse Effects
Side effects of Olanzapine :
>10%
Orthostatic hypotension (>20%),Weight gain, dose dependent (5-40%),Hypertriglyceridemia (<39%),Hypercholesterolemia (<39%),Somnolence, dose dependent (6-39%),Extrapyramidal symptoms (EPS), dose dependent (15-32%),Xerostomia (9-22%),Weakness (2-20%),Dizziness (4-18%),Accidental injury (12%),Insomnia (12%),Elevated alanine aminotransferase (ALT) level (5-12%),Constipation (9-11%),Dyspepsia (7-11%),Hyperprolactinemia (30%),Hyperglycemia (12.8%)
1-10%
Hypotension (2%),Postural hypotension (1%),Tremor (1%),Asthenia (2%),Akathisia reactions (2%),Parkinsonism reactions (4%)
<1%
Syncope,Sudden cardiac death,Hyperglycemia,Diabetic coma with ketoacidosis,Diabetic ketoacidosis,Acute hemorrhagic pancreatitis,Venous thromboembolism,Immune hypersensitivity reaction,Cerebrovascular disease,Seizure, status epilepticus,Suicidal intent,Pulmonary embolism,Death,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia
Potentially Fatal: Exacerbation of preexisting diabetes sometimes leading to ketoacidosis. Neuroleptic malignant syndrome.
Mechanism of Action
Olanzapine is an atypical antipsychotic with affinity for serotonin 5-HT2A/2C, dopamine, muscarinic M1-M5, histamine H1 and adrenergic ?1 receptors.
Note
Zafrin 2.5 2.5mg Tablet manufactured by Magnus Pharma Pvt. Ltd.. Its generic name is Olanzapine. Zafrin 2.5 is availble in Nepal.
Farmaco Nepal drug index information on Zafrin 2.5 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.